Health-related quality-of-life (HRQoL) analysis from a randomized phase II trial of androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415.

Andrey Soares,Diogo Assed Bastos,Fabio A.B. Schutz,Eduardo Cronemberger,Murilo Luz,Suelen Patrícia dos Santos Martins,David Queiroz Borges Muniz,Flavio Mavignier Cárcano,Oren Smaletz,Fabio A. Peixoto,Andrea Juliana Pereira de Santana Gomes,Felipe Melo Cruz,Fábio André Franke,Daniel Herchenhorn,Rosemarie Gidekel,Taiane Francieli Rebelatto,Rafaela Gomes,Vinícius Carrera Souza,André P. Fay,Fernando C. Maluf

Health-related quality-of-life (HRQoL) analysis from a randomized phase II trial of androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415.

2021

64Background: LACOG0415 is a 3-arm randomized trial evaluating ADT with abiraterone acetate plus prednisone (ADT+AAP), apalutamide alone (APA) or apalutamide with AAP (APA+AAP) for patients with lo...

Keywords:

Apalutamide
Oncology
Prednisone
Abiraterone acetate
Androgen
health related quality of life
Androgen deprivation therapy
Castration-sensitive prostate cancer
Internal medicine
Medicine
Randomized controlled trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations